Nurix Therapeutics Q2 2024 Earnings Report

Nurix Therapeutics EPS Results

• Actual EPS: -$0.71
• Consensus EPS: -$0.63
• Beat/Miss: Missed by -$0.08
• One Year Ago EPS: N/A

Nurix Therapeutics Revenue Results

• Actual Revenue: $12.09 million
• Expected Revenue: $19.35 million
• Beat/Miss: Missed by -$7.26 million
• YoY Revenue Growth: N/A

Nurix Therapeutics Announcement Details

• Quarter: Q2 2024
• Date: 7/11/2024
• Time: TAS
• Conference Call Date: Thursday, July 11, 2024
• Conference Call Time: 4:00PM ET

Nurix Therapeutics (NASDAQ:NRIX) is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development. Among these are targeted protein degraders designed to eliminate key signaling proteins implicated in B-cell malignancies and inflammatory disorders. Nurix advances both proprietary and partnered assets, leveraging its Maestro™ platform to generate novel therapeutic candidates that reflect its expertise in medicinal chemistry, structural biology and protein degradation technologies.

Founded in 2015 and headquartered in San Francisco, California, Nurix collaborates with leading pharmaceutical companies to accelerate discovery and development. These strategic alliances complement the company’s in-house capabilities, enabling the translation of early research into clinical candidates and enhancing its capacity to address diseases that have proved difficult to treat with conventional approaches.

Under the leadership of Chief Executive Officer Christalynn Sayers and an experienced management team, Nurix Therapeutics continues to advance its proprietary pipeline through clinical trials and regulatory engagements. The company remains committed to pioneering new modalities that selectively dismantle disease drivers, with the goal of delivering transformative medicines to patients worldwide.